New Drug Report Shows Record Need For Harm Reduction And Support Services
A new report that pulls together the most recent data on drug consumption, prevalence of use, price and availability shows illicit drug use continues to steadily increase across the board, with the NZ Drug Foundation warning that investment in harm reduction, early intervention and support hasn't kept pace.
The Foundation's latest annual Drug use in Aotearoa report for 2023/24 shows sharp increases in methamphetamine and cocaine consumption, and an uptick in frequency of use.
Drug Foundation Executive Director Sarah Helm says the report underlines the need for greater investment in harm reduction and support services.
'This report shows there is more need than ever for accessible harm reduction information and early intervention so that we can help people prevent issues before they arise,' she says.
'The sharp increase in cocaine and methamphetamine use has happened against the backdrop of long-term under-investment in addiction services and the sector is now under intense strain. We urgently need to turn that around.'
While New Zealand has historically seen low levels of cocaine use, consumption increased 229% in 2024 compared with the previous three years' average. Methamphetamine use increased 74% over the same period.
Helm says the report also shows that people are using cocaine and methamphetamine more often.
'Information from the NZ Drug Trends Survey shows that of people who used cocaine, 29% reported using it monthly or more often in 2024, compared with 22% in 2017/18,' she says.
'Worryingly, 29% of people who used methamphetamine in the past six months reported using it daily or near daily in 2024, up from only 19% in 2022/23.'
'This increase in the proportion of people using methamphetamine daily or near daily is concerning, and suggests we will see a significant uptick in people with substance use disorder,' says Helm.
'Unfortunately, the support systems we have were already strained before these latest increases in problematic use.'
Cannabis, MDMA and psychedelics were the most commonly used illicit drugs in New Zealand, which Helm says all rank down the lower end of potential for harm.
'Many of our most popular illicit substances have well-documented medicinal uses and are being actively studied for their potential to treat a range of health conditions, so it's likely at least some of the use in this report is self-medication,' she says.
"We think it's time to enable more medical access to the likes of psychedelics and MDMA and stop prosecuting people who use them.'
Helm says the big increases in cocaine and methamphetamine use demonstrate the folly of New Zealand's 50-year-old drug laws.
'Our current system feels like we have control, but the data shows it's quite the opposite. This report shows methamphetamine and cocaine use has surged despite record-breaking drug busts and seizures, and anecdotally we are hearing about increased harm as a result.'
'Under our current laws we have relinquished almost all control to the global black market, which in recent years has sold record-breaking amounts of cocaine and methamphetamine into the country.'
Key findings:
Methamphetamine
Nationwide, consumption doubled in the second half of 2024 (compared to the first half of the year)
29% of people who use methamphetamine reported using it daily or near daily in 2024, up from 19% in 2022/23
Cocaine
Consumption more than tripled in 2024 compared to the previous three years' average (although this was off a low base)
2.4% of adults reported using cocaine at least once in the past year in 2023/24, compared with 1.3% in 2022/23
Cocaine use is much more common among men (3.6%) than among women (1.3%)
MDMA
4.8% of adults reported using MDMA at least once in the past year in 2023/24, compared with 3.6% in 2022/23
Young people are more likely to use MDMA than older New Zealanders. 10.5% of people aged 15-24 reported using MDMA at least once in the past year in 2023/24, compared with 8.2% in 2022/23
Psychedelics
3.1% of adults reported using psychedelics at least once in the past year in 2023/24, compared with 1.3% in 2017/18
62% of psychedelic consumers reported that LSD is 'easy' or 'very easy' to obtain in 2024, compared with 44% in 2017/18.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
15 hours ago
- RNZ News
Call for more medical access to commonly used illicit drugs
Prescription psilocybin, the hallucinogenic compound found in magic mushrooms, will become available to treat prescription-resistant depression. Photo: Pixabay The Drug Foundation wants more medical access to some of the most commonly used illicit drugs. It comes after the government announced prescription psilocybin , the hallucinogenic compound found in magic mushrooms, will become available to treat prescription-resistant depression. The Drug Foundation's annual report found psychedelic drug use has more than doubled in New Zealand, with 3.1 percent of adults reported taking psychedelics like LSD, psilocybin and ketamine in 2023 and 2024, compared to 1.3 percent in 2017 and 2018. It said cannabis, MDMA, and psychedelics rank down the lower end of the potential harm spectrum, and have well-documented medical uses. The Drug Foundation's executive director Sarah Helm said some people are self-medicating with such drugs, and are being criminalised by not being allowed to access them legally. "Many of our most popular illicit substances have well-documented medicinal uses and are being actively studied for their potential to treat a range of health conditions, so it's likely at least some of the use in this report is self-medication," Helm said. "We think it's time to enable more medical access to the likes of psychedelics and MDMA and stop prosecuting people who use them." In Australia, MDMA, known as ecstasy in tablet form, is being used to help treat post-traumatic stress disorder (PTSD). While earlier this year, a clinical study using mushrooms containing psilocybin to treat methamphetamine addiction completed its first phase of trials. "Criminalising anyone doesn't really help, whether the substance use is problematic or therapeutic," Helm told Morning Report. " Certainly, they [psychedelics] have been stigmatised and that's prevented access." NZ Drug Foundation executive director Sarah Helm. Photo: Supplied/ NZ Drug Foundation The release of these numbers coincides with Associate Health Minister David Seymour's announcement that psilocybin would be legally available in New Zealand outside of trials for the first time. It brings New Zealand in line with Australia, which has been using psilocybin to treat depression since 2023 . Seymour said it would initially only be available from one specific psychiatrist, but he hoped more would apply. The psychiatrist, Ōtautahi -based Dr Cameron Lacey, who was also behind the first clinical trials of psilocybin, said about two thirds of people who participated in clinical trials saw substantial improvements in their depression. "It's truly providing remarkable results and it's really exciting to see a treatment that is providing real benefit for people who typically, at that point in their treatment journey, had a really long road and low improvement from standard treatments," Dr Lacey told Morning Report. Dr Cameron Lacey. Photo: Supplied The therapy involves months of psychotherapy and one or two eight-hour psilocybin sessions or 'doses' accompanied by clinical professionals. Most of the studies have involved one or two doses integrated with a course of psychotherapy. For some, just one treatment can be sufficient . "The most important thing that we need to work on next is making sure this treatment is available to all who need it," Dr Lacy said. Helm said the announcement that the magic mushroom drug psilocybin will be available for some patients is good news, but better access is needed. "We do need to see a broader range of clinicians making it available, otherwise people do turn to self-administration. It's happens in the cannabis field, as well. It is about balancing," Helm said. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
Scoop
a day ago
- Scoop
New Drug Report Shows Record Need For Harm Reduction And Support Services
A new report that pulls together the most recent data on drug consumption, prevalence of use, price and availability shows illicit drug use continues to steadily increase across the board, with the NZ Drug Foundation warning that investment in harm reduction, early intervention and support hasn't kept pace. The Foundation's latest annual Drug use in Aotearoa report for 2023/24 shows sharp increases in methamphetamine and cocaine consumption, and an uptick in frequency of use. Drug Foundation Executive Director Sarah Helm says the report underlines the need for greater investment in harm reduction and support services. 'This report shows there is more need than ever for accessible harm reduction information and early intervention so that we can help people prevent issues before they arise,' she says. 'The sharp increase in cocaine and methamphetamine use has happened against the backdrop of long-term under-investment in addiction services and the sector is now under intense strain. We urgently need to turn that around.' While New Zealand has historically seen low levels of cocaine use, consumption increased 229% in 2024 compared with the previous three years' average. Methamphetamine use increased 74% over the same period. Helm says the report also shows that people are using cocaine and methamphetamine more often. 'Information from the NZ Drug Trends Survey shows that of people who used cocaine, 29% reported using it monthly or more often in 2024, compared with 22% in 2017/18,' she says. 'Worryingly, 29% of people who used methamphetamine in the past six months reported using it daily or near daily in 2024, up from only 19% in 2022/23.' 'This increase in the proportion of people using methamphetamine daily or near daily is concerning, and suggests we will see a significant uptick in people with substance use disorder,' says Helm. 'Unfortunately, the support systems we have were already strained before these latest increases in problematic use.' Cannabis, MDMA and psychedelics were the most commonly used illicit drugs in New Zealand, which Helm says all rank down the lower end of potential for harm. 'Many of our most popular illicit substances have well-documented medicinal uses and are being actively studied for their potential to treat a range of health conditions, so it's likely at least some of the use in this report is self-medication,' she says. "We think it's time to enable more medical access to the likes of psychedelics and MDMA and stop prosecuting people who use them.' Helm says the big increases in cocaine and methamphetamine use demonstrate the folly of New Zealand's 50-year-old drug laws. 'Our current system feels like we have control, but the data shows it's quite the opposite. This report shows methamphetamine and cocaine use has surged despite record-breaking drug busts and seizures, and anecdotally we are hearing about increased harm as a result.' 'Under our current laws we have relinquished almost all control to the global black market, which in recent years has sold record-breaking amounts of cocaine and methamphetamine into the country.' Key findings: Methamphetamine Nationwide, consumption doubled in the second half of 2024 (compared to the first half of the year) 29% of people who use methamphetamine reported using it daily or near daily in 2024, up from 19% in 2022/23 Cocaine Consumption more than tripled in 2024 compared to the previous three years' average (although this was off a low base) 2.4% of adults reported using cocaine at least once in the past year in 2023/24, compared with 1.3% in 2022/23 Cocaine use is much more common among men (3.6%) than among women (1.3%) MDMA 4.8% of adults reported using MDMA at least once in the past year in 2023/24, compared with 3.6% in 2022/23 Young people are more likely to use MDMA than older New Zealanders. 10.5% of people aged 15-24 reported using MDMA at least once in the past year in 2023/24, compared with 8.2% in 2022/23 Psychedelics 3.1% of adults reported using psychedelics at least once in the past year in 2023/24, compared with 1.3% in 2017/18 62% of psychedelic consumers reported that LSD is 'easy' or 'very easy' to obtain in 2024, compared with 44% in 2017/18.
Scoop
29-05-2025
- Scoop
Smokefree 2025: A Promise Gone Up In Smoke
Press Release – Asthma and Respiratory Foundation of New Zealand As the globe marks World Smokefree Day this Saturday, 31 May, the Asthma and Respiratory Foundation NZ is reminding Kiwis that this was the year New Zealand was meant to become smokefree. Smokefree 2025 was within reach. Now, it's a milestone we're set to miss. As the globe marks World Smokefree Day this Saturday, 31 May, the Asthma and Respiratory Foundation NZ is reminding Kiwis that this was the year New Zealand was meant to become smokefree. 'Instead, the Government rolled back the clock and stoked the fire, derailing years of public health progress,' Foundation Chief Executive Ms Letitia Harding says. Ms Harding says there is little to celebrate and much to be concerned about. 'We were on track to lead the world in tobacco control, now we appear to be leading the world in vaping. 'Our previous Smokefree laws were bold, evidence-based, and targeted at protecting future generations, but the repeal of those measures blindsided everyone.' The Foundation has been one of the strongest advocates for a smokefree Aotearoa for many years. It backed policies that would have phased out tobacco sales for future generations, reduced nicotine levels, and supported drastically cutting the number of retailers. Back in 2021, the Foundation celebrated the bold steps taken toward Smokefree 2025, calling it a 'significant step forward' in reducing respiratory disease and health inequities, particularly for Māori and Pacific communities. Fast forward to today, and the mood has shifted. The Foundation has been vocal in its disappointment over the coalition Government's decision to roll back key Smokefree laws, warning about the implications to the health of New Zealanders and a missed opportunity to lead the world in tobacco control. At the same time, the Foundation is deeply concerned by the new approach to achieving Smokefree Aotearoa – simply shifting the problem to vapes. 'The Government's strategy seems to be 'let's just add vapes to the mix', which is just another product that has harmful health effects and ensures future generations are nicotine dependent,' said Ms Harding. 'As we have said previously, that rationale is like letting stoats in to eradicate rabbits – that's not a solution. 'We're not breaking the cycle of nicotine dependency – we're just redirecting it,' she says. 'Let's free Aotearoa from the shackles of big tobacco, who make money on the back of nicotine dependency.' The goal shouldn't just be a smokefree New Zealand – it should be vape-free too, Ms Harding says. 'Otherwise, we're just chasing a new kind of addiction – and calling it progress.'
